摘要
目的探讨对原发性肝癌(primary liver cancer,PLC)骨转移患者采用唑来膦酸联合局部放疗的疗效和安全性。方法收集我院2018年1月至2019年6月收治的76例PLC骨转移患者并分成两组,对照组给予局部放疗,观察组在对照组的基础上给予唑来膦酸联合局部放疗;观察两组的肿瘤标志物、骨代谢、肝功能和生活质量指标的变化,以及药物不良反应。结果治疗前,两组的miR-21和TNF-α肿瘤标志物,OST和BAP骨代谢指标,ALT、ALP和TBIL肝功能水平,以及VAS和Barthel评分生活质量指标比较,差异无统计学意义(P>0.05);治疗3个月后,观察组的肿瘤标志物、骨代谢、肝功能和生活质量指标水平均较对照组改善(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论对PLC骨转移患者采用唑来膦酸联合局部放疗,能抑制癌症基因表达水平,改善骨代谢和疾病预后,用药安全性高。
Objective To investigate the efficacy and safety of Zoledronic acid combined with local radiotherapy in patients with primary liver cancer(PLC) bone metastasis. Methods Seventy-six patients with HCC metastasis in recent years were divided into two groups. The control group received local radiotherapy and the observation group received Zoledronic acid combined with local radiotherapy. Changes in tumor markers, bone metabolism, liver function and quality of life, as well as adverse drug reactions were observed in the two groups. Results Before treatment, there was no difference in miR-21 and TNF-α tumor markers, OST and BAP bone metabolism indicators, liver function levels of ALT, ALP and TBIL, VAS and Barthel scores(P>0.05). After 3 months of treatment, tumor markers, bone metabolism, liver function and quality of life indexes in the observation group were all improved compared with those in the control group(P<0.05). There was no difference in adverse reactions between the two groups(P>0.05).Conclusion Zoledronic acid combined with local radiotherapy for PLC patients with bone metastasis can improve the inhibition of cancer gene expression, improve bone metabolism and disease prognosis, and ensure high drug safety.
作者
徐晓美
沈预程
邵春燕
XU Xiaomei;SHEN Yucheng;SHAO Chunyan(Department of Oncology,Hai’an Hospital Affiliated to Nantong University,Haian 226600,China)
出处
《胃肠病学和肝病学杂志》
CAS
2021年第7期822-825,共4页
Chinese Journal of Gastroenterology and Hepatology
基金
南通市2018年度市级科技计划项目(MSZ18192)。
